{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:37:03Z","timestamp":1786977423481,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T00:00:00Z","timestamp":1268265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4\u2010week treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>To optimize dose, schedule, and route of alemtuzumab, a study was designed exploring continuous intravenous infusion (civ) followed by subcutaneous (sc) alemtuzumab together with weekly iv rituximab in patients with previously treated CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Data from 40 patients with a median age of 59 years, and a median of 3 prior regimens (range, 1\u20108 regimens) were evaluable. Approximately 64% of patients were fludarabine\u2010refractory. Seven patients (18%) achieved a complete response (CR), 4 (10%) a nodular partial response (nPR), and 10 (25%) a partial response for an overall response rate of 53%. Of 11 major responses (CR, nPR), 8 occurred after cycle 1. Response rates were highest in blood (94%), followed by liver\/spleen (82%), bone marrow (68%), and lymph nodes (51%). The combination did not generate unexpected toxicities. Cytomegalovirus (CMV) reactivations occurred in 6 patients (15%) and responded well to anti\u2010CMV therapy. High titers of anti\u2010idiotype antibodies after sc alemtuzumab were demonstrated in 1 patient, but remained without clinical sequelae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>The combination of civ\/sc alemtuzumab plus rituximab has activity in some patients with recurrent\/refractory CLL and maximum response is achieved after 1 cycle (4 weeks) in 73% of patients. Further exploration in other settings of CLL together with accompanying pharmacokinetic studies is recommended. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.24958","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T16:47:03Z","timestamp":1268326023000},"page":"2360-2365","source":"Crossref","is-referenced-by-count":24,"title":["Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence"],"prefix":"10.1002","volume":"116","author":[{"given":"Stefan","family":"Faderl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60456-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.457"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1952"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.01023.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0593"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood.V112.11.325.325","article-title":"Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression\u2010free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemoa (CLL) [abstract]","volume":"112","author":"Hallek M","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"LBA\u20101","DOI":"10.1182\/blood.V112.11.lba-1.lba-1","article-title":"Rituximab, fludarabine, and cyclophosphamide (R\u2010FC) prolongs progression free survival in relapsed or refractory chronic lymphoyctic leukemia (CLL) compared with FC alone: final results from the International Randomized Phase III REACH Trial","volume":"112","author":"Robak T","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20477"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1182\/blood.V112.11.2098.2098","article-title":"Alemtuzumab and rituximab combination therapy for patients with untreated CLL\u2010a phase II trial","volume":"112","author":"Frankfurt O","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23824"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24958","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:06:45Z","timestamp":1760267205000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,5,15]]}},"alternative-id":["10.1002\/cncr.24958"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24958","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,28]]}}}